$CGC

Lazzarato David Angelo sold $21K of CGC

Lazzarato David Angelo sold 22,674 shares of Canopy Growth Corp (CGC) at $0.92 on 2026-06-26.

Original reporting
SEC EDGAR · Lazzarato David Angelo
Published Jun 29, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

A director’s open-market sale of 22,674 shares at $0.9237/share is disclosed; the filing does not include any new operational or financial guidance.

02

Market read

Traders may note insider selling, but the transaction size (~$21k) and lack of accompanying fundamental news make it unlikely to drive a major repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or personal liquidity needs; without additional context (e.g., other insiders selling/buying, changes in compensation), the signal is weak.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-29 after-hours; reflects sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction for Canopy Growth Corp (CGC), reported via SEC EDGAR.

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

SEC Form 4 shows director Lazzarato David Angelo sold 22,674 CGC shares on 2026-06-26 at $0.9237/share.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact is likely short-lived.

Evidence & confidence

The filing discloses a single insider sale size (~$21k) with no 10b5-1 plan, but it is not accompanied by new company fundamentals, guidance, or material corporate action.

Market effects

No sector read-across; this is an isolated insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale was not under a 10b5-1 plan, some traders may interpret it as a stronger near-term caution signal than a scheduled plan—though the dollar value is small.

Key entities

  • Canopy Growth Corp

    Subject of the Form 4 insider transaction disclosure.

  • Lazzarato David Angelo

    Director who sold 22,674 shares on 2026-06-26.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$CGCMedAI 8/10

Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?

Canopy Growth Corporation (CGC) shares rose 15% in a month after reporting Q1 fiscal 2027 earnings that beat estimates, showing revenue growth and improved margins. The company's cannabis business is improving, with increased revenues and narrowing losses. However, cash flow remains a concern, and competition in the cannabis market is stiff. Analysts have slightly improved loss estimates but maintain a 'Hold' rating.

$CURLFMedAI 8/10

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf launched an unsolicited offer to buy Aurora Cannabis for $272 million, or $4 per share, about a 45% premium to Aurora’s 30-day VWAP, aiming for about $1.5 billion revenue, $350 million adjusted EBITDA, and $40 million annual cost synergies. The article also discusses whether Canopy Growth could be a future acquisition target, citing its turnaround and global medical cannabis platform.